Clinical trials
Completed Diabetic Neuropathies trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
103 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 6 |
| 2003 | 2 |
| 2004 | 7 |
| 2005 | 7 |
| 2006 | 10 |
| 2007 | 7 |
| 2008 | 9 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 5 |
| 2013 | 6 |
| 2014 | 5 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 103 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eli Lilly and Company | 6 |
| Sangamo Therapeutics | 5 |
| Helixmith Co., Ltd. | 4 |
| BioDelivery Sciences International | 3 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 3 |
| UCB Pharma | 3 |
| AbbVie (prior sponsor, Abbott) | 2 |
| AstraZeneca | 2 |
| Chromaderm, Inc. | 2 |
| Eastern Virginia Medical School | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetic Neuropathies | 103 |
| Diabetes Mellitus | 30 |
| Pain | 20 |
| Neuralgia | 12 |
| Diabetes Mellitus, Type 1 | 8 |
| Diabetes Mellitus, Type 2 | 8 |
| Diabetic Foot | 6 |
| Peripheral Nervous System Diseases | 5 |
| Chronic Pain | 4 |
| Diabetes Complications | 3 |
Trials
Showing 1 to 25 of 103. Each trial links to its page on Pharma Observatory.
3 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.